: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage.
: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown. NEWM-035
If clinical trials continue to show success, researchers aim to make TRG-035 commercially available by . This would offer a biological alternative to traditional prosthetic solutions like dental implants, bridges, or dentures. Japan Begins Human Trials for Tooth Regrowth Drug TRG-035 : Launched in September 2024 at Kyoto University Hospital
The code appears to be a misnomer or a very specific internal project identifier for which there is no broad public record. However, it is most frequently associated in recent medical research contexts with TRG-035 , a groundbreaking tooth regeneration drug currently undergoing human clinical trials in Japan. In nature, USAG-1 acts as a "biological parking
: Preclinical trials on mice and ferrets—chosen for their similar dental structures—successfully produced new teeth with normal enamel and root structures and no significant side effects.
: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials
The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi.